Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Revenue of Generation Bio Co. (GBIO)
Revenue in 2023 (TTM): $5.9 M
According to Generation Bio Co.'s latest financial reports the company's current revenue (TTM) is $5.9 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Generation Bio Co.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5.9 M | $-73,911,000 | $-133,300,000 | $-126,612,000 | $-126,612,000 |
| 2022 | $ | $-5,130,000 | $-136,052,000 | $-136,639,000 | $-132,096,000 |
| 2021 | $ | $-4,532,000 | $-114,569,000 | $-119,151,000 | $-114,669,000 |
| 2020 | $ | $-3,432,000 | $-77,682,000 | $-80,523,000 | $-76,500,000 |
| 2019 | $ | $-1,864,000 | $-60,438,000 | $-61,317,000 | $-60,332,000 |
| 2018 | $36 K | $36 K | $-36,947,000 | $-35,803,000 | $-35,803,000 |